Coated (e.g., Microcapsules) Patents (Class 424/490)
  • Patent number: 10703954
    Abstract: Methods for treating a subterranean formation are described. The methods include providing a petrified cellulosic material, combining the petrified cellulosic material with a treatment fluid, and introducing the treatment fluid with the petrified cellulosic material in the subterranean formation.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: July 7, 2020
    Inventors: Cato Russell McDaniel, Dale E. Jamison
  • Patent number: 10682409
    Abstract: This invention discloses a treatment for a patient receiving medication to treat an attention deficit disorder such as ADHD wherein the treatment results in a loss of appetite and impairment of the patient's attentiveness. The treatment combines a treatment for an attention deficit disorder with an appetite stimulant, wherein the appetite stimulant increases the caloric intake of a patient, which can increase the patient's attentiveness. The combination treatment can be given for an indefinite, including, without limitation, life-long, to allow a patient to maintain normal caloric intake during treatment for an attention deficit disorder.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 16, 2020
    Assignee: Attentive Therapeutics, Inc.
    Inventors: Douglas Sears, Michael Reilly
  • Patent number: 10682314
    Abstract: Disclosed herein are methods and compositions for treating or preventing swine influenza in a subject.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: June 16, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Renukaradhya Gourapura, Santosh Dhakal, Jagadish Hiremath, Chang-Won Lee
  • Patent number: 10676701
    Abstract: A consumer product composition comprises a consumer product adjunct ingredient, a microcapsule, and deposition polymer disposed on an outer surface of the microcapsule. The deposition polymer has a Water Uptake Value (WUV) of at least about 2 grams per gram, as determined according to the WATER UPTAKE VALUE TEST METHOD. The microcapsule comprises a shell material encapsulating a core material, wherein the shell material comprises a polyacrylate and the core material comprises a benefit agent.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: June 9, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Hiroshi Oh, Dorothy A Hall, Pierre Verstraete, Olivier Fasbender, Johan Smets, Steven Daryl Smith
  • Patent number: 10646485
    Abstract: The present disclosure relates to cured pharmaceutical compositions designed to reduce the potential for improper administration of drugs that are subject to abuse, the process of curing such composition in order to improve the dissolution stability, method of using the same for treatment of pain.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 12, 2020
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Said Saim, Alison B. Fleming, Ravi K. Varanasi
  • Patent number: 10632069
    Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: April 28, 2020
    Assignee: Adare Pharmaceuticals US, L.P.
    Inventors: Stephen Perrett, Fredric Jay Cohen, Gopi Venkatesh
  • Patent number: 10617651
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 14, 2020
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 10583282
    Abstract: A nanodevice includes an array of metal nanorods formed on a substrate. An electropolymerized electrical conductor is formed over tops of a portion of the nanorods to form a reservoir between the electropolymerized conductor and the substrate. The electropolymerized conductor includes pores that open or close responsively to electrical signals applied to the nanorods. A cell loading region is disposed in proximity of the reservoir, and the cell loading region is configured to receive stem cells. A neurotrophic dispensing material is loaded in the reservoir to be dispersed in accordance with open pores to affect growth of the stem cells when in vivo.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: March 10, 2020
    Assignee: International Business Machines Corporation
    Inventors: Steven J. Holmes, Qinghuang Lin, Emily R. Kinser, Nathan P. Marchack, Roy R. Yu
  • Patent number: 10576065
    Abstract: The present invention relates to a pharmaceutical composition containing rifaximin in the form of two different polymorphs as well as a method of preparing the same.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: March 3, 2020
    Assignee: Sandoz AG
    Inventor: Johannes Raneburger
  • Patent number: 10576028
    Abstract: The present invention concerns a composition, in particular in the form of aqueous dispersion for caring for and/or making up keratin materials comprising, in a physiologically acceptable medium, a) one aqueous phase; and b) at least microcapsules comprising:—an inner core comprising at least a dispersion of at least one reflective agent, in particular bismuth oxychloride, in at least one oil, and—at least one outer shell formed of a wall-forming polymeric material surrounding the said core, the said outer shell comprising i) at least one wall-forming polymer, and ii) optionally at least one plasticizer and/or at least one opaque substance and/or at least one fatty acid salt. The present invention concerns also a cosmetic process for caring for and/or making up keratinic materials, comprising application on said keratinic materials in particular on the skin of a composition as above defined.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: March 3, 2020
    Assignee: L'OREAL
    Inventors: Audrey Ricard, Danny Goldstein
  • Patent number: 10562781
    Abstract: One embodiment of the present disclosure provides a method for producing an angle-independent colloidal particles-based structure, the method having: preparing two or more types of hollow colloidal particles, wherein the types are distinguished based on a size of the hollow colloidal particles thereof, wherein the types have different particle sizes; and dispersing the at least two types of hollow colloidal particles to produce an amorphous structure, wherein the amorphous structure realizes the same color independently of an angle of an incident light thereto.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 18, 2020
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventors: Seung Hyun Kim, Gi Ra Yi
  • Patent number: 10561603
    Abstract: The present invention provides a core-shell structure having high skin permeability. The core-shell structure includes a core portion containing a hydrophilic drug having a molecular weight of 400 or more; and a shell portion containing a surfactant, and the core portion is a solid, the hydrophilic drug has a water-octanol partition coefficient of ?3 or more and 6 or less, the surfactant has an alkyl group or an alkenyl group having 10 to 20 carbon atoms, and a mass ratio between the hydrophilic drug and the surfactant (hydrophilic drug:surfactant) is 1:5 to 1:20.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: February 18, 2020
    Inventors: Takayuki Akamine, Kazushi Itou, Saori Tone, Yoshiko Abe
  • Patent number: 10532028
    Abstract: A method for preparing solid materials is described. One aspect of the method includes the steps of providing a mixture comprising an organic material in a blend of a solvent and non-solvent for the organic material, distributing the mixture into either droplets or granules, and evaporating the solvent and non-solvent mixture to form particles having an average size of from about 0.5 ?m to about 5000 ?m.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: January 14, 2020
    Inventor: John Alfred Doney
  • Patent number: 10525000
    Abstract: A solid cosmetic composition includes (i) a natural colourant, (ii) starch, and (iii) mica.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: January 7, 2020
    Inventors: Mark Constantine, Margaret Joan Constantine, Helen Elizabeth Ambrosen, Rowena Jacqueline Bird
  • Patent number: 10517832
    Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 31, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
  • Patent number: 10517818
    Abstract: A method of preparing an orally ingestible hard boiled product, comprising: i) heating a sugar material to a first temperature sufficient to liquefy the sugar material; ii) cooling the liquefied sugar material to provide a cooled sugar material having a solid or semi-solid form; iii) heating the cooled sugar material to a second temperature, which is lower than the first temperature; iv) combining the sugar material with one or more temperature sensitive ingredients before, during, or after said heating step iii), but after said cooling step ii), such that an intimate mixture of the second liquefied sugar material and the one or more temperature sensitive ingredients is provided; and v) cooling the intimate mixture to form an orally ingestible product. Orally ingestible hard boiled products prepared according to this method are also provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 31, 2019
    Assignee: R.J. Reynolds Tobacco Company
    Inventors: Thaddeus J. Jackson, Frank Kelley St. Charles
  • Patent number: 10512658
    Abstract: The invention describes novel compositions and methods utilized for treating disorders and/or conditions associated with the epidermal and/or dermal level of the skin. Such disorders include hyperhidrosis, bromhidrosis, and chromhidrosis, One representative composition of the invention comprises; water, alcohol, aluminum sesquichlorohydrate, hydroxypropyl methyl cellulose, polysorbate 20, isopropyl myristate, eucalyptus oil, silicone oil, alkyl benzoate, glycerine, talc, a hydrophillic silica, a hydrophobic silica, phenoxyethanol and ethylhexyl glycerine.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: December 24, 2019
    Assignee: Clutch, Inc.
    Inventors: David Bradley Spratte, Jr., Christopher Jenks, Kasper Kubica, Mary Claire Brehm, Shari Deanna Angelina Fonte Clemente
  • Patent number: 10509016
    Abstract: Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: December 17, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Beatrisa Boyadzhyan, Karin Thomassian, Anita Dermartirosian, Lou Jambor
  • Patent number: 10500162
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: December 10, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
  • Patent number: 10493122
    Abstract: The present invention provides Glatiramer acetate compositions in a non-gelling matrix, formulated for sublingual delivery.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: December 3, 2019
    Assignee: MAPI PHARMA LTD.
    Inventors: Yoram Sela, Ehud Marom, Nadav Bleich Kimelman
  • Patent number: 10493083
    Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 3, 2019
    Assignee: CMP Development LLC
    Inventors: Anthony Pipho, Michael Paul DeHart
  • Patent number: 10485798
    Abstract: Methylnaltrexone nasal formulations are discloses which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: November 26, 2019
    Assignee: APTAPHARMA INC.
    Inventor: Siva Rama K. Nutalapati
  • Patent number: 10478400
    Abstract: The present disclosure relates generally to rapid-release pharmaceutical dosage unit tablets containing a drug that is an inhibitor of the mitogen-activated protein kinase enzyme, a filler and a disintegrant, and to processes for forming the tablets. More specifically, the present disclosure relates to pharmaceutical dosage unit tablets containing cobimetinib, a least one filler, at least one lubricant and at least one disintegrant, and to methods for preparing the tablets from granules formed by dry granulation.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: November 19, 2019
    Assignee: Genentech, Inc.
    Inventors: Sanjeev Kothari, Priscilla Mantik, Alexander Mauerer, Hamid Rezaei
  • Patent number: 10480081
    Abstract: Disclosed is a method of manufacturing a dishwasher including: forming a first layer containing zirconium oxide and silicon oxide on a surface of the inner wall at a heat treatment of 200° C. or higher; forming a second layer containing an oxoacid on a surface of the first layer at a heat treatment temperature lower than the heat treatment temperature of the first layer; and obtaining a thin-film layer containing zirconium oxide and silicon oxide on the surface of the inner wall and having a contact angle of water of 20° or less on the surface, after removing the second layer by using a washing method, in which the first layer contains the zirconium oxide in an amount of 80 mass % or more in terms of oxide and the silicon oxide in an amount of 1-20 mass % in terms of oxide.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: November 19, 2019
    Inventor: Keijiro Shigeru
  • Patent number: 10471093
    Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: November 12, 2019
    Assignee: Cour Pharmaceuticals Development Company.
    Inventors: Daniel R. Getts, Rachael Terry, Nicholas King
  • Patent number: 10472379
    Abstract: The described invention provides a compound comprising an organometallic complex comprising a core of ruthenium and sphingomyelin, with the option of added zinc, that, in a therapeutic amount, through further connections with contributing organic ligands, are effective as chemotherapeutic agents that have an anti-tumor or anti-cancer effect on a tumor comprising tumor cells including a cytotoxic effect on of the tumor cells, inhibition of the growth of the tumor comprising the tumor cells, inhibition of migration of the tumor cells, or any combination of these effects.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: November 12, 2019
    Inventor: Merrill Garnett
  • Patent number: 10471159
    Abstract: Processes of intraoperative diagnosis and elimination of tumors or micro-tumors or cancer cells or tumor micro-environment (TME) with plasmonic nanobubbles (PNBs) are disclosed. The diagnosis and surgical processes disclosed can improve standard onco-surgery through one or more of the following: real-time intraoperative local detection of MRD in vivo with high cancer sensitivity and specificity; real-time guidance of surgery to precisely eliminate resectable MRD with minimal morbidity by resecting only PNB-positive volume instead of a larger volume; intraoperative selective elimination of unresectable MRD through the mechanical impact of lethal cancer cell-specific PNBs without damaging adjacent normal cells and tissues; and prediction of the surgical outcome through the metrics of PNB signals.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: November 12, 2019
    Assignee: Masimo Corporation
    Inventors: Dmitri O. Lapotko, Katsiaryna Hleb
  • Patent number: 10463619
    Abstract: Compositions and methods of making and using of microparticle compositions that provide faster flow or improved injectability through smaller or small-diameter needles have been developed. Notably, the microparticle compositions can be successfully delivered or administered through smaller-diameter needles than other microparticle compositions prepared from biocompatible or biodegradable polymers including, for example, poly(lactide), poly(lactide-co-glycolide), polycaprolactone, or poly-3-hydroxybutyrate. The microparticle compositions can exhibit a higher solids loading for a given needle size and/or faster flow through needles than other microparticle compositions. Further, blending or mixing the polymer of the microparticle composition with other polymer formulations can enhance the injectability of the resulting formulation.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: November 5, 2019
    Inventors: Peter Markland, Gary Anthony Winchester, Thomas Robert Tice, David P. Martin
  • Patent number: 10463871
    Abstract: Disclosed embodiments enable apparatus and methodologies that are provided for three-dimensional construction of tissues in the body at locations internal to the body.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: November 5, 2019
    Assignee: Weinberg Medical Physics Inc
    Inventors: Irving N. Weinberg, Aleksandar Nelson Nacev, Lamar Odell Mair
  • Patent number: 10465042
    Abstract: Polymers including poly(amine-co-ester), poly(amine-co-amide), or a combination thereof, and nanoparticles, particularly solid core nanoparticles, formed therefrom are provided. Solid core nanoparticles fabricated from hydrophobic polymers often require the presence of cationic complexing agents to stabilize negatively charged active agents such as siRNA. However, complexing agents are optional in the disclosed formulations because the nanoparticles contain cationic amines to stabilize negatively charged nucleic acids and hydrophobic domains to condense the nucleic acid into the core of the formed nanoparticles, thus improving encapsulation efficiency. This increase in nucleic acid loading allows the disclosed solid core nanoparticles to deliver more nucleic acid per cell without increasing total polymer delivered, further reducing cytotoxicity.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: November 5, 2019
    Inventors: Jiajia Cui, Junwei Zhang, W. Mark Saltzman
  • Patent number: 10456374
    Abstract: The present invention relates to pyrrolidone carboxylic acid (PCA) and/or pharmaceutically acceptable salts or derivatives thereof for use in the treatment of ocular diseases and/or disorders. A further object of the present invention are compositions comprising pyrrolidone carboxylic acid (PCA) and/or pharmaceutically acceptable salts or derivatives thereof, at least one physiologically acceptable excipient, and optionally at least one additional active ingredient for use in the treatment of ocular diseases and/or disorders.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: October 29, 2019
    Assignee: Laboratori Baldacci S.p.A.
    Inventor: Massimo Baldacci
  • Patent number: 10426765
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 1, 2019
    Inventors: Georg Waetzig, Dirk Seegert
  • Patent number: 10420725
    Abstract: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analog or derivative thereof.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: September 24, 2019
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Peter Persicaner, Craig Judy
  • Patent number: 10398726
    Abstract: A template-free method of preparing zeolites from biomass can include using rice husk ash waste material as a precursor material. The zeolites can include ZSM-5 zeolites, such as, hierarchical pure zeolites and metal-loaded (Cu, Ni) ZSM-5 zeolites. This method allows for production of zeolites in a low cost and environmentally friendly manner. These ZSM-5 zeolites may be used for numerous applications, including killing cancer cells. The cancer cells may be human lung cancer cells.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: September 3, 2019
    Assignee: King Saud University
    Inventors: Jothi Ramalingam, Jesu Doss, Judith Vijaya, Hamad Al-Lohedan
  • Patent number: 10391058
    Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: August 27, 2019
    Assignee: NANOBIOTIX
    Inventors: Matthieu Germain, Marie-Edith Meyre, Agnes Pottier, Laurent Levy
  • Patent number: 10357462
    Abstract: A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: July 23, 2019
    Assignee: Ben Research, Inc.
    Inventors: Dwayne Thomas Friesen, Leah E. Appel, Joshua Richard Shockey, Sanjay Konagurthu, Edward Dennis LaChapelle
  • Patent number: 10350272
    Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: July 16, 2019
    Assignee: KeyBioscience AG
    Inventors: Morten Karsdal, Kim Henriksen, Kim Vietz Andreassen, Sofie Gydesen, Sara Toftegaard Hjuler
  • Patent number: 10342870
    Abstract: The invention provides therapeutic magnetic nanoparticles containing a therapeutic agent connected to a magnetic nanoparticle core through a stable functional group and a linker that can be induced to release the therapeutic agent from the core, through hydrolysis of the functional group. Also provided are methods for making nanoparticles, and methods for using nanoparticles.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: July 9, 2019
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Michael H. Nantz, Ralph Knipp
  • Patent number: 10335390
    Abstract: Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: July 2, 2019
    Assignee: Symbiomix Therapeutics, LLC
    Inventors: Helen S. Pentikis, David Palling, Carol J. Braun
  • Patent number: 10307511
    Abstract: The present invention generally relates to bioactive composites of polymer and glass and, more particularly, to bioactive implants. The present invention also relates to methods of manufacturing bioactive composites. The bioactive composite finds utility in a variety of load-bearing clinical applications including spine, orthopaedic and dental procedures.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: June 4, 2019
    Assignee: Orthovita, Inc.
    Inventors: Theodore D. Clineff, Marissa M. Conrad, Matthew B. Havener, James P. Murphy, Zachary S. Szczerbinski
  • Patent number: 10300023
    Abstract: A non-covalently assembled hydrogel or organo-gel composition with serum stability is described. Low molecular weight (<2,500 Da), generally regarded as safe (GRAS), materials assemble in the presence of a stabilizing agent at an appropriate molar percentage, forming hydrogel or organo-gel with nanostructures that resist disassembly or destabilization in serum for an extended period of time. The composition is used to deliver one or more therapeutic, prophylactic, or diagnostic agents, allowing for controlled release in response to biological stimuli such as enzymes and a greatly improved dosing efficacy.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 28, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jeffrey M. Karp, Nitin Joshi, Nikken Wiradharma, Kai Vincent Slaughter
  • Patent number: 10293056
    Abstract: The present invention relates to non-viral gene therapy methods and compositions for treatment of hyperproliferative disease in humans. More specifically, the invention is directed, in one embodiment, to lipid formulations which form stable liposome structures, capable of efficient in vivo nucleic acid transfer. In other embodiments, methods and compositions are directed to liposome transfer of anti-proliferative nucleic acids, wherein the transfer of the nucleic acids is cell specific via cell specific targeting moieties. The present invention, thus provides non-viral, liposome compositions and methods of gene transfer particularly useful for targeting and treating hyperproliferative disease.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: May 21, 2019
    Assignees: Board of Regents, The University of Texas System, Introgen Research Institute, Inc.
    Inventors: Rajagopal Ramesh, Jack A. Roth, Tomoyuki Saeki, Deborah R. Wilson
  • Patent number: 10285933
    Abstract: A personal care composition includes an ozone-stressed yeast lysate; and a preservative, in which the preservative is selected from phenoxyethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, butylene glycol, pentylene glycol, methylparaben, propylparaben, butylparaben, benzalkonium chloride, Quaternium 15, methylisothiazolinone, methylchloroisothiazolinone, DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, butylated hydroxytoluene, tocopherol, triclosan, chlorohexidine digluconate, and combinations thereof, and the ozone-stressed yeast lysate is produced by a method including exposing growing yeast to ozone by aerating the yeast for a time period of between five minutes and seventy-two hours with an aeration gas having an ozone concentration of from 0.0001 millimolar (mM) to 1.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: May 14, 2019
    Inventor: James Vincent Gruber
  • Patent number: 10278927
    Abstract: Systems and methods for coating a particle core with a layer-by-layer film are disclosed.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: May 7, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Paula T. Hammond, Zhiyong Poon
  • Patent number: 10251871
    Abstract: Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-T cell agent, an anti-TGF-?1 agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 9, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Babak Mehrara, Jason Gardenier, Ira Savetsky, Omer Aras
  • Patent number: 10247719
    Abstract: Disclosed herein are generally to methods and systems that facilitate imaging of cells on a substrate and more particularly to pre-implantation (in vitro) and post-implantation (in vivo) imaging of cell-seeded substrates implanted in target tissues in the context of stem cell therapy.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: April 2, 2019
    Inventors: Mark Humayun, Ashish Ahuja, Charles Le Pere
  • Patent number: 10245322
    Abstract: Methods, systems, and devices are disclosed for fabricating and implementing nanoscale and microscale structured carriers to provide guided, targeted, and on-demand delivery of molecules and biochemical substances for a variety of applications including diagnosis and/or treatment (theranostics) of diseases in humans and animals. In some aspects, a nanostructure carrier can be synthesized in the form of a nanobowl, which may include an actuatable capping particle that can be opened (and in some implementations, closed) on demand. In some aspects, a nanostructure carrier can be synthesized in the form of a hollow porous nanoparticle with a functionalized interior and/or exterior to attach payload substances and substances for magnetically guided delivery and controlled release of substance payloads.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: April 2, 2019
    Assignee: The Regents of the University of California
    Inventors: Ratneshwar Lal, Preston B. Landon, Alexander Mo
  • Patent number: 10233261
    Abstract: A method of making natural polymer (nano)particles, comprises two immiscible phases and a surface active agent, wherein one phase includes a natural polymer source and ionic liquid; stirring the combined phases with surfactant to form a microemulsion; adjusting the ratios of ionic liquid, surfactant, and immiscible phase to determine a particular size of natural polymer nanoparticles; stirring antisolvent into the emulsion; diluting the emulsion; and washing and drying precipitated polymer (nano)particles from the emulsion. The immiscible phase comprises at least one of immiscible solvent, oil, or immiscible ionic liquid. The ionic liquid phase includes natural polymer dissolved in ionic solvent. The antisolvent is water, other protic solvent or additive. The emulsion is diluted with, more immiscible phase, 1-butanol, or a mutually miscible solvent, or oil. The emulsion is diluted with an excess of the volume of the emulsion.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: March 19, 2019
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jeffrey Alston, Joseph Mabry, Andrew Guenthner
  • Patent number: 10213446
    Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: February 26, 2019
    Assignee: BIOrest Ltd.
    Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
  • Patent number: 10203325
    Abstract: The disclosure relates to metal nanoparticle compositions and their methods of formation and use, in particular gold nanoparticles (AuNP) and gold-coated magnetic nanoparticles. Compositions according to the disclosure include aqueous suspensions of metal nanoparticles that are stabilized with one or more carbohydrate capping agents and/or that are functionalized with one or more binding pair members for capture/detection of a target analyte. The nanoparticle suspensions are stable for extended periods and can be functionalized as desired at a later point in time, typically prior to use in an assay for the detection of a target biological analyte. The stable nanoparticle suspension can be formed by the aqueous reduction of oxidized metal precursors at non-acidic pH values in the presence of a carbohydrate-based capping agent such as dextrin or other oligosaccharides.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: February 12, 2019
    Inventors: Evangelyn C. Alocilja, Hanna Miller